Depression is a leading global cause of functional disability and is typically treated with antidepressants or psychotherapy.
However, a substantial number of patients do not respond to two well-implemented treatment attempts, leading to treatment-resistant depression.
A new study shows that it might significantly increase their risks of mortality.
A study of depression and mortality risks
A recent study in JAMA Psychiatry found that individuals with treatment-resistant depression face a 23% higher risk of mortality compared to others with depression.
They also require twice as much outpatient care and spend three times as many days in hospitals.
This research, conducted by Karolinska Institutet and others, underscores the importance of identifying those at risk for treatment-resistant depression.
The study, based in the Stockholm region, analyzed data from over 145,000 depressed patients between 2012 and 2017, identifying over 12,000 cases of treatment-resistant depression.
Those with treatment-resistant depression utilized healthcare resources more extensively, had higher mortality rates, and experienced comorbid psychiatric conditions like anxiety and substance abuse.
Why it's important
Early prediction of treatment resistance, particularly based on the severity of depression, emerged as a crucial factor.
Reducing the time it takes for patients to undergo two treatment attempts, currently averaging 1.5 years, could lead to better outcomes.
Identifying at-risk patients and promptly switching to more effective treatments like lithium could enhance care and alleviate the societal burden of this patient group.
